NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-4000
August 30, 2017
Share
NantCell, Inc. has entered into licensing agreement with GlobeImmune, Inc. for exclusive worldwide rights to the GlobeImmune's GI-4000 program, mutated Ras oncogene product. Under the agreement, GI-4000 will be evaluated in combination with multiple additional agents in patients with metastatic pancreas cancer, triple negative breast cancer (TNBC), ovarian cancer, urothelial cancer, head and neck squamous cell cancer, metastatic colorectal cancer and NSCLC, whose tumors express mutations in the Ras oncogene product. Concurrently, NantCell has entered into licensing agreement with GlobeImmune for exclusive rights to develop, manufacture and commercialize the GI-6207 and GI-6301. Concurrently, NantCell has exercised its option to enter into licensing agreement with GlobeImmune for GI-6100. Under the terms of the agreement, GlobeImmune is entitled to receive payments on the achievement of certain product development and commercialization milestones and royalties based on net sales of products by NantCell or its affiliates or sublicensees.
GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Companyâs Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.